J. Crawford

649 total citations
43 papers, 518 citations indexed

About

J. Crawford is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, J. Crawford has authored 43 papers receiving a total of 518 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 6 papers in Pathology and Forensic Medicine. Recurrent topics in J. Crawford's work include Lung Cancer Treatments and Mutations (14 papers), Neutropenia and Cancer Infections (10 papers) and Cancer Treatment and Pharmacology (7 papers). J. Crawford is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Neutropenia and Cancer Infections (10 papers) and Cancer Treatment and Pharmacology (7 papers). J. Crawford collaborates with scholars based in United States, United Kingdom and Italy. J. Crawford's co-authors include Daniel F. Hayes, Claudine Isaacs, Everett E. Vokes, Mathew J. Ellis, Vered Stearns, Cecilia Tibery, Baljit Singh, Bruce D. Cheson, Rebecca Slack and Theodore N. Tsangaris and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

J. Crawford

41 papers receiving 495 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Crawford United States 12 271 173 137 86 85 43 518
Fulvio Brema Italy 12 388 1.4× 67 0.4× 79 0.6× 86 1.0× 136 1.6× 36 562
Tomasz Sarosiek Poland 14 313 1.2× 107 0.6× 154 1.1× 44 0.5× 54 0.6× 38 754
M. Holtkamp Netherlands 9 220 0.8× 37 0.2× 128 0.9× 99 1.2× 81 1.0× 13 442
Ettinger Ds United States 12 170 0.6× 126 0.7× 116 0.8× 17 0.2× 33 0.4× 21 429
Bohumil A. Samal United States 8 196 0.7× 68 0.4× 32 0.2× 42 0.5× 73 0.9× 13 359
S Schryber United States 8 258 1.0× 77 0.4× 76 0.6× 143 1.7× 107 1.3× 9 435
A Fontana France 10 324 1.2× 89 0.5× 133 1.0× 78 0.9× 39 0.5× 25 505
Kiyohiko Dohi Japan 14 168 0.6× 257 1.5× 183 1.3× 12 0.1× 78 0.9× 43 751
Marwan Yared United States 12 176 0.6× 53 0.3× 103 0.8× 90 1.0× 74 0.9× 20 523
V. Barbounis Greece 15 231 0.9× 115 0.7× 102 0.7× 38 0.4× 85 1.0× 31 481

Countries citing papers authored by J. Crawford

Since Specialization
Citations

This map shows the geographic impact of J. Crawford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Crawford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Crawford more than expected).

Fields of papers citing papers by J. Crawford

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Crawford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Crawford. The network helps show where J. Crawford may publish in the future.

Co-authorship network of co-authors of J. Crawford

This figure shows the co-authorship network connecting the top 25 collaborators of J. Crawford. A scholar is included among the top collaborators of J. Crawford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Crawford. J. Crawford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Stephen V., et al.. (2019). MA09.01 A Phase I/II Trial of Dasatinib and Osimertinib in TKI Naïve Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 14(10). S281–S282. 2 indexed citations
2.
Subramaniam, Deepa S., Stephen V. Liu, J. Crawford, et al.. (2018). A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung Cancer. Frontiers in Oncology. 8. 64–64. 13 indexed citations
3.
Christie, Fiona, et al.. (2012). Optimising postoperative fluid administration. European Journal of Anaesthesiology. 29. 43–43. 1 indexed citations
4.
Hanna, Rabbie K., Marek S. Poniewierski, Robin Laskey, et al.. (2011). Relationship between relative dose intensity and mortality in women receiving combination chemotherapy for stage III-IV epithelial ovarian cancer.. Journal of Clinical Oncology. 29(15_suppl). 5084–5084. 4 indexed citations
5.
Strauss, Gary M., Michael A. Maddaus, David W. Johnstone, et al.. (2011). Adjuvant chemotherapy (AC) in stage IB non-small cell lung cancer (NSCLC): Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9633.. Journal of Clinical Oncology. 29(15_suppl). 7015–7015. 14 indexed citations
6.
Poniewierski, Marek S., et al.. (2008). Reduced chemotherapy dose intensity in patients with ovarian cancer: Results from a prospective nationwide study. Journal of Clinical Oncology. 26(15_suppl). 16508–16508. 3 indexed citations
7.
Lyman, Gary H., et al.. (2008). Impact of pegfilgrastim on early all-cause mortality in patients receiving cancer chemotherapy. Journal of Clinical Oncology. 26(15_suppl). 6552–6552. 4 indexed citations
8.
9.
10.
11.
Cosler, Leon E., Adi Eldar‐Lissai, David C. Dale, J. Crawford, & Gary H. Lyman. (2005). Economic analysis of pegfilgrastim in patients receiving cancer chemotherapy. Journal of Clinical Oncology. 23(16_suppl). 6041–6041. 6 indexed citations
12.
13.
Crawford, J., et al.. (2004). Cricoid pressure: a simple, yet effective biofeedback trainer. European Journal of Anaesthesiology. 21(6). 443–447. 25 indexed citations
14.
Crawford, J., et al.. (2004). Cricoid pressure: a simple, yet effective biofeedback trainer. European Journal of Anaesthesiology. 21(6). 443–447. 25 indexed citations
15.
Daniel, Davey B., et al.. (2004). Risk and mortality associated with febrile neutropenia in lung cancer patients. Journal of Clinical Oncology. 22(14_suppl). 7223–7223. 1 indexed citations
16.
Stearns, Vered, Baljit Singh, Theodore N. Tsangaris, et al.. (2003). A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.. PubMed. 9(1). 124–33. 84 indexed citations
17.
18.
19.
Leopold, K., et al.. (1993). Carboplatin, etoposide, and radiotherapy, followed by surgery, for the treatment of marginally resectable non-small cell lung cancer. Cancer Treatment Reviews. 19. 53–62. 6 indexed citations
20.
Crawford, J.. (1971). A review of 41 cases of myasthenia gravis subjected to thymectomy. Anaesthesia. 26(4). 513–513. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fulvio Brema Breakdown of academic impact, for papers by Tomasz Sarosiek Breakdown of academic impact, for papers by M. Holtkamp Breakdown of academic impact, for papers by Ettinger Ds Breakdown of academic impact, for papers by Bohumil A. Samal Breakdown of academic impact, for papers by S Schryber Breakdown of academic impact, for papers by A Fontana Breakdown of academic impact, for papers by Kiyohiko Dohi Breakdown of academic impact, for papers by Marwan Yared Breakdown of academic impact, for papers by V. Barbounis
Rankless by CCL
2026